Vir's CMO says he's surprised that a low dose of their hepatitis B drug appears promising in early slice of data — shares soar
Initial topline data from a Phase I study of a new therapeutic for chronic hepatitis B virus was so promising that it surprised even the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
